BioMaxima Valuation
Is BMX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BMX (PLN13.8) is trading above our estimate of fair value (PLN7.89)
Significantly Below Fair Value: BMX is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BMX?
Key metric: As BMX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BMX's PS Ratio? | |
|---|---|
| PS Ratio | 1.2x |
| Sales | zł48.97m |
| Market Cap | zł57.87m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 31.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BMX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.9x | ||
CRM PZ Cormay | 0.5x | n/a | zł38.3m |
MRC Mercator Medical | 0.9x | n/a | zł463.1m |
MDA MedApp | 8.8x | n/a | zł46.8m |
MDG Medicalgorithmics | 5.6x | n/a | zł196.1m |
BMX BioMaxima | 1.2x | n/a | zł57.9m |
Price-To-Sales vs Peers: BMX is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (3.9x).
Price to Sales Ratio vs Industry
How does BMX's PS Ratio compare vs other companies in the European Medical Equipment Industry?
| 33 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 33 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: BMX is good value based on its Price-To-Sales Ratio (1.2x) compared to the European Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is BMX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BMX's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.